INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Miller Thomas F. reported IAM

Director, Chief Executive Officer · Iambic Therapeutics, Inc. · Common Stock

Side
A
Value
—
Shares
132.2K
Price
—
Executed
Oct 14, 2026
Disclosed
Oct 16, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 14 executedOct 16, 2026 disclosed

IAM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 10.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IAM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    742.5K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    410.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    2.00M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    57.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.14M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    731.2K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    122.7K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    742.5K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    17
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    410.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    49
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Open-market purchase
    		BUY$11.50M
    718.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.15M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    57.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    306.7K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    2.00M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    742.5K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.14M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002034921-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 14, 2026
    Published
    Oct 16, 2026
    Ingested by INSIDER
    Nov 5, 02:11 UTC
    Last re-read
    Nov 5, 02:11 UTC

    Extracted facts

    Filer
    Miller Thomas F.
    Role
    Director, Chief Executive Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Iambic Therapeutics, Inc.
    Ticker
    IAM
    Shares
    132.2K
    Price per share
    $0
    Execution date (reported)
    Oct 14, 2026
    Owned after transaction
    1.41M shares
    Days from execution to publication
    2

    What this establishes

    Miller Thomas F. filed this Form 4 reporting a grant or award of IAM on Oct 14, 2026. It became public on Oct 16, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Miller Thomas F.cik:0002034921
    Issuer
    Iambic Therapeutics, Inc.cik:0001997038

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.